- Home
- PACB
as 11-22-2024 3:38pm EST
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 452.1M | IPO Year: | 2010 |
| Target Price: | $2.92 | AVG Volume (30 days): | 12.8M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $10.65 | Next Earning Date: | 11-07-2024 |
| Revenue: | $173,147,000 | Revenue Growth: | 2.14% |
| Revenue Growth (this year): | -15.89% | Revenue Growth (next year): | 25.88% |
Stock Insider Trading Activity of Pacific Biosciences of California Inc. (PACB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kim Susan G. | PACB | See Remarks | Sep 30 '24 | Sell | $1.72 | 19,782 | $34,064.60 | 695,654 | |
| HENRY CHRISTIAN O | PACB | See Remarks | Sep 16 '24 | Sell | $1.75 | 98,907 | $172,691.62 | 2,497,763 |
Latest Pacific Biosciences of California Inc. News
PACB Breaking Stock News: Dive into PACB Ticker-Specific Updates for Smart Investing
Insider Monkey
5 days ago
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now
Motley Fool
12 days ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Simply Wall St.
12 days ago
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
MT Newswires
13 days ago
UBS Downgrades Pacific Biosciences of California to Neutral From Buy, Cuts Price Target to $2 From $12
Simply Wall St.
15 days ago
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
GlobeNewswire
16 days ago
PacBio to Present at Upcoming Investor Conferences
Zacks
16 days ago
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
GuruFocus.com
16 days ago
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ...
Compare PACB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PACB Pacific Biosciences of California Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.